Investor Outreach: Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $75,000 in Capricor Therapeutics between October 9, 2024, and July 10, 2025, to contact partner Josh Wilson for legal discussions.
Class Action Deadline: The firm is investigating potential claims against Capricor and reminds investors of the September 15, 2025, deadline to seek the role of lead plaintiff in a federal securities class action against the company.
CAPR
$26.28+Infinity%1D
Analyst Views on CAPR
Wall Street analysts forecast CAPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAPR is 36.38 USD with a low forecast of 20.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast CAPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAPR is 36.38 USD with a low forecast of 20.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.150
Low
20.00
Averages
36.38
High
60.00
Current: 26.150
Low
20.00
Averages
36.38
High
60.00
B. Riley
B. Riley
Buy
maintain
$21 -> $50
2025-12-15
New
Reason
B. Riley
B. Riley
Price Target
$21 -> $50
2025-12-15
New
maintain
Buy
Reason
B. Riley raised the firm's price target on Capricor Therapeutics to $50 from $21 and keeps a Buy rating on the shares. The clinical data support a higher probability of Deramiocel approval, with statistically significant and clinically meaningful efficacy across primary and key secondary endpoints, positioning it as a potential first disease-modifying therapy for DMD and associated cardiomyopathy with a favorable safety profile, the analyst tells investors in a research note. Updated assumptions reflect a 75% probability of success, approximately $380M in pro forma cash, and $1.1B in risk-adjusted net sales by 2030, with substantial royalty-driven upside for Capricor, the firm says.
Piper Sandler
NULL
to
Overweight
upgrade
$20 -> $45
2025-12-10
Reason
Piper Sandler
Price Target
$20 -> $45
2025-12-10
upgrade
NULL
to
Overweight
Reason
Piper Sandler raised the firm's price target on Capricor Therapeutics to $45 from $20 and keeps an Overweight rating on the shares. The firm notes last Wednesday, the Phase III HOPE-3 trial met the primary endpoint showing a significant 1.2 point absolute difference from placebo in the Performance of the Upper Limb 2.0. Deramiocel also met the key cardiac endpoint showing an absolute 2.4% improvement in LVEF, representing a 91% slowing of decline vs. placebo. Capricor will submit HOPE-3 data as a response to the FDA's CRL under the current BLA for deramiocel in DMD cardiomyopathy by year-end 2025. Piper anticipates a Type II 6-month review resulting in potential deramiocel approval by mid-2026.
Oppenheimer
Oppenheimer
Outperform
maintain
$22 -> $54
2025-12-08
Reason
Oppenheimer
Oppenheimer
Price Target
$22 -> $54
2025-12-08
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Capricor Therapeutics to $54 from $22 and keeps an Outperform rating on the shares following deramiocel's broadly positive Phase 3 results and the company's financing. The firm believes deramiocel's clinical profile stands second to none relative to approved Duchenne muscular dystrophy therapeutics, and its projected 2031 sales of about $1.1B in the U.S. alone through partner NS Pharma may prove conservative.
Maxim
Maxim
Buy
maintain
$25 -> $50
2025-12-04
Reason
Maxim
Maxim
Price Target
$25 -> $50
2025-12-04
maintain
Buy
Reason
Maxim raised the firm's price target on Capricor Therapeutics to $50 from $25 and keeps a Buy rating on the shares. The firm cites the company's top-line data from the HOPE-3 trial for Deramiocel ) in Duchenne muscular dystrophy meeting both the primary endpoint of PuL2.0 and the key secondary endpoint of left ventricular ejection fraction at statistically significant levels, as well as other measures, the analyst tells investors in a research note. The data demonstrated both skeletal and cardiac benefits, which tracked with prior observations in both the HOPE-2 phase 2 and HOPE-2 open-label extension, the firm added.
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
